文献速递血管炎

Avacopan联合环磷酰胺治疗ANCA相关血管炎的疗效与安全性

Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide.
PubMed 文献 · RMD Open · 2025-10-05

ADVOCATE试验亚组分析纳入116例接受环磷酰胺(CYC)的ANCA相关血管炎患者(avacopan组59例,泼尼松减量组57例),第26周缓解率avacopan组62.7% vs 泼尼松减量组59.6%,第52周持续缓解率55.9% vs 52.6%;52周内复发率avacopan组13.0% vs 泼尼松减量组22.6%,eGFR改善、白蛋白尿下降速度及糖皮质激素毒性差异均倾向于avacopan组,严重不良事件发生率两组相似(55.9% vs 56.1%)。

要点

  • 接受CYC的GPA或MPA患者中,avacopan组与泼尼松减量组第26周缓解率及第52周持续缓解率相似。
  • 52周内复发率avacopan组13.0% vs 泼尼松减量组22.6%,avacopan组数值上更低。
  • eGFR改善、UACR下降速度及糖皮质激素毒性差异均倾向于avacopan组,严重不良事件发生率两组相似。

核心结论

  • 在接受CYC的GPA或MPA患者中,avacopan组与泼尼松减量组缓解率相似,avacopan方案与数值上更低的复发率、更大的eGFR改善、更快的UACR下降、更低的糖皮质激素相关毒性及相似的总体安全性相关,结果支持avacopan联合CYC治疗GPA或MPA。

研究设计与样本

  • ADVOCATE试验(NCT02994927)亚组分析,纳入接受CYC序贯硫唑嘌呤(或吗替麦考酚酯)的ANCA相关血管炎(GPA或MPA)患者,接受研究药物的330例患者中116例(35.2%)接受CYC,其中avacopan组59例、泼尼松减量组57例。

主要发现

  • 第26周缓解:avacopan组37/59(62.7%)vs 泼尼松减量组34/57(59.6%)。
  • 第52周持续缓解:avacopan组33/59(55.9%)vs 泼尼松减量组30/57(52.6%)。
  • 52周内复发:avacopan组13.0% vs 泼尼松减量组22.6%。
  • 严重不良事件:avacopan组55.9% vs 泼尼松减量组56.1%。
  • eGFR改善、白蛋白尿下降速度及糖皮质激素毒性差异均倾向于avacopan组。

关键数值与推荐

  • 第26周缓解率avacopan组62.7%(37/59)vs 泼尼松减量组59.6%(34/57)。
  • 第52周持续缓解率avacopan组55.9%(33/59)vs 泼尼松减量组52.6%(30/57)。
  • 52周内复发率avacopan组13.0% vs 泼尼松减量组22.6%。
  • 严重不良事件发生率avacopan组55.9% vs 泼尼松减量组56.1%。

临床怎么用

  • 在接受CYC的GPA或MPA患者中,avacopan联合CYC方案与泼尼松减量方案缓解率相似,且与数值上更低的复发率、更大的eGFR改善、更快的UACR下降及更低的糖皮质激素相关毒性相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluated the efficacy and safety of avacopan versus a prednisone taper in the subgroup of patients with antineutrophil cytoplasmic antibody-associated vasculitis (granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)) receiving cyclophosphamide (CYC) followed by azathioprine (or mycophenolate mofetil) in the ADVOCATE trial. METHODS: Key efficacy outcomes were remission at week 26 and sustained remission at week 52. Additional outcomes included glucocorticoid toxicity, estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (UACR) and safety. RESULTS: Of 330 patients receiving study medication, 116 (35.2%) received CYC (avacopan group, n=59; prednisone taper group, n=57). Remission at week 26 and sustained remission at week 52 were achieved by 37/59 (62.7%) and 33/59 (55.9%) patients in the avacopan group and 34/57 (59.6%) and 30/57 (52.6%) in the prednisone taper group, respectively. Over 52 weeks, relapses were observed in 13.0% in the avacopan group and 22.6% in the prednisone taper group. Improvement in eGFR, speed of albuminuria reduction and differences in glucocorticoid toxicity favoured the avacopan group. Serious adverse events occurred in 55.9% and 56.1% of patients in the avacopan and prednisone taper groups, respectively. CONCLUSIONS: This subgroup analysis of patients who received CYC shows similar rates of remission in the avacopan and prednisone taper groups. Compared with the prednisone taper regimen, the avacopan regimen was associated with a numerically lower relapse rate, greater improvement in eGFR, faster reduction in UACR, lower glucocorticoid-related toxicity and similar overall safety. These results support the use of avacopan in combination with CYC to treat GPA or MPA. TRIAL REGISTRATION NUMBER: NCT02994927.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Geetha D, Neumann T, Karras A, et al. Efficacy and safety of avacopan for treatment of patients with ANCA-associated vasculitis receiving cyclophosphamide. RMD Open. 2025. PMID: 41052893. doi:10.1136/rmdopen-2025-005743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。